Ronovo Surgical is a technology company.
Ronovo Surgical has raised $27.0M across 1 funding round.
Ronovo Surgical has raised $27.0M in total across 1 funding round.
Ronovo Surgical has raised $27.0M in total across 1 funding round.
Ronovo Surgical's investors include AMR Action Fund, Boehringer Ingelheim Venture Fund, Vivo Capital.
Ronovo Surgical is a Shanghai-based medtech company founded in 2019 that develops the Carina™ platform, a modular soft tissue robotic surgery system for minimally invasive procedures in general surgery, gynecology, urology, and thoracic surgery.[1][2][3] The Carina robot serves hospitals and surgeons by enabling precise laparoscopic surgeries with flexible configurations, addressing limitations of legacy systems like high costs and rigidity through independent mobile carts, adaptable instruments (8-mm wristed and 5-mm straight), and compatibility with existing laparoscopic setups.[1][2][3] It solves key challenges in robotic-assisted surgery (RAS) by improving flexibility, affordability, and ease of integration into operating rooms, while supporting both robotic and conventional laparoscopic use.[1][3] The company has raised over $168M across Series B, C, and D rounds (including $67M in Series D led by J&J's JJDC in 2025), achieved NMPA approval in China in March 2025, and begun international expansion with regulatory submissions in Europe and South America, signaling strong growth momentum.[1][2]
Ronovo Surgical was founded in 2019 by CEO John Ma, a former Intuitive Surgical executive, and Ying Mao, chief operating and technology officer from Auris Health (acquired by J&J).[2][5] Operating from Shanghai's tech hub, the company emerged to tackle unmet clinical needs in robot-assisted minimally invasive surgery, accelerating from concept to commercialization of the Carina platform in just four years with over 200 global patents.[3] Early traction included stealth-mode development with 140 employees focused on R&D and clinical work by 2022, rapid clinical trials (e.g., multicenter enrollment in 2024), and key milestones like launching the Ronovo Institute for Surgical Excellence (RISE) in Orlando, US, establishing a global manufacturing base in Yangzhou, and securing NMPA approval in March 2025.[3][5] A pivotal partnership with Johnson & Johnson Medical Shanghai in 2025 expanded sales of Carina alongside J&J products, boosting commercial rollout.[2]
Ronovo stands out in surgical robotics through its Carina™ platform's innovative design:
These features democratize access, as emphasized by CEO John Ma.[2]
Ronovo rides the global surge in surgical robotics, challenging Intuitive Surgical's dominance amid demand for affordable, flexible soft tissue systems amid aging populations and rising minimally invasive surgery (MIS) adoption.[2] Timing aligns with China's medtech boom, post-NMPA approval enabling domestic scaling, while J&J partnerships and international filings (Europe, South America) position it for export growth.[2][3] Market forces like cost barriers of incumbents and J&J's own Ottava entry (FDA submission Q1 2026) favor Ronovo's modular, adaptable model, which integrates with existing infrastructure to accelerate hospital uptake.[1][2] It influences the ecosystem by fostering academic exchanges, clinical training (e.g., RISE institute), and collaborations, promoting RAS as standard for MIS and empowering global surgeons with precision tools.[3]
Ronovo is poised for accelerated global expansion post-2025 funding and approvals, with J&J alliances driving China sales and international regulatory wins unlocking Europe and South America markets.[2] Trends like AI-enhanced vision, cost pressures on robotics, and multi-specialty MIS growth will shape its path, potentially capturing share from legacy players through Carina's modularity.[2][3] Influence may evolve via expanded manufacturing, more clinical trials (e.g., urology successes), and ecosystem building, solidifying Ronovo as a democratizer of robotic surgery worldwide—aligning with its mission to empower MIS with digital intelligence for superior patient outcomes.[1][3]
Ronovo Surgical has raised $27.0M across 1 funding round. Most recently, it raised $27.0M Series B in August 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2023 | $27.0M Series B | AMR Action Fund, Boehringer Ingelheim Venture Fund, Vivo Capital |